Feline allergic dermatitis study

picture of cat

Current Status: Open and enrolling
Principal Investigator: Sheila Torres, DVM, MS, PhD, DACVD
Contacts: Dr. Torres: torre009@umn.edu
Kelly Bergsrud, Senior Research Study Technician, kbergsru@umn.edu,
612-624-9597

Study purpose and design:

Feline allergic dermatitis (AD) affects around 10-12% of the cat population. Cats with feline AD have chronic itching that can result in hair loss, skin inflammation, scratched areas, and more. This study is researching the safety and effectiveness of an investigational product compared to placebo in reducing the signs of AD in cats. Owners will bring their cat to the Veterinary Medical Center (VMC) five times over two months. The study investigational product or placebo will be given once on Day 0. Owners will assess their cats at home and at the study visits.

Eligible cats, briefly (contact us for full information):

  • Have a history of allergic dermatitis and currently have clinical signs 
  • In otherwise good health
  • Have been on an effective flea/tick control product for the past 30 days or more and have no current infestations
  • Willing to withdraw from steroidal and antihistamine medications (plus others, contact us)
  • Will remain on allowed medications with no change throughout the study
  • Will remain on the same diet throughout the study
  • Do not have malignant cancer, or positive FIV or FeLV tests
  • Are not intended for breeding, or lactating
  • Do not have any abnormalities in pretreatment blood counts, serum chemistry or urinalysis

Costs of the study

The study visits and study injection are paid by the study. In addition, at the conclusion of the study, owners will be eligible for a $500 debit card provided all study visits are completed.

To learn more, or to enroll, please contact Kelly Bergsrud or Dr. Torres (above).